Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0017 | 0.0313 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0048 | 0.254 | 1 |
Brugia malayi | glutathione reductase | 0.0048 | 0.254 | 0.3284 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0048 | 0.254 | 0.2985 |
Trypanosoma brucei | trypanothione reductase | 0.0048 | 0.254 | 1 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0017 | 0.0313 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0121 | 0.7736 | 1 |
Treponema pallidum | NADH oxidase | 0.0017 | 0.0313 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0122 | 0.7773 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0017 | 0.0313 | 0.5 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0048 | 0.254 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0017 | 0.0313 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0048 | 0.254 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0017 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0109 | 0.6906 | 0.8837 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0048 | 0.254 | 1 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0109 | 0.6906 | 0.8837 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0017 | 0.0313 | 0.0405 |
Brugia malayi | Thioredoxin reductase | 0.0048 | 0.254 | 0.3284 |
Brugia malayi | MH2 domain containing protein | 0.0121 | 0.7736 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0048 | 0.254 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0048 | 0.254 | 1 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0109 | 0.6906 | 0.8837 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0048 | 0.254 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0017 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable reductase | 0.0109 | 0.6906 | 0.8837 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0017 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0109 | 0.6906 | 0.8837 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0017 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0122 | 0.7773 | 1 |
Leishmania major | trypanothione reductase | 0.0048 | 0.254 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0017 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0109 | 0.6906 | 0.8837 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0122 | 0.7773 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0048 | 0.254 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0122 | 0.7773 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0121 | 0.7736 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.8584 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.3753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.